10:06:53 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-22 Kvartalsrapport 2024-Q1
2024-05-02 Ordinarie utdelning ACOU 0.00 SEK
2024-04-30 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-04-26 Ordinarie utdelning ACOU 0.00 SEK
2023-04-25 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning ACOU 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-12-21 Extra Bolagsstämma 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-15 Ordinarie utdelning ACOU 0.00 SEK
2021-02-24 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-10 Ordinarie utdelning ACOU 0.00 SEK
2020-06-09 Årsstämma 2020
2020-05-27 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-06-18 Ordinarie utdelning ACOU 0.00 SEK
2019-06-17 Årsstämma 2019
2019-05-22 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-06-14 Ordinarie utdelning ACOU 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-03-21 Extra Bolagsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-11-24 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-06-19 Ordinarie utdelning ACOU 0.00 SEK
2017-06-16 Årsstämma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-11-25 Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
AcouSort är verksamt inom medicinteknik. Idag har bolaget en utvecklad plattformsteknologi inriktad mot akustofores, som med hjälp utav ultraljud separerar och analyserar biologiska cellers sammansättningar. Tekniken används huvudsakligen vid analys av cancerfall och sepsis (blodförgiftning). En stor del av forskningen sker i samarbete med övriga aktörer inom Life-Science. Bolaget etablerades under 2010 och har sitt huvudkontor i Lund.
2024-04-30 09:55:00

Today, April 30, 2024, the annual general meeting was held in AcouSort AB (publ). Below is a summary of the decisions that were made. All decisions were made with the required majority.

Profit allocation and decision on discharge from liability.
The meeting approved the income statement and balance sheet for both the parent company and the group. The meeting decided to dispose of the company's results according to the board's proposal in the annual report. The meeting further decided that no dividend will be paid for the financial year 2023. In addition, the meeting decided to discharge the members of the board and the CEO for the financial year 2023.
 
Determining the fees for the board and auditor
The meeting decided that the board should consist of four board members and no board deputy, and that no remuneration should be paid to the board. Furthermore, the meeting decided that an auditor and no deputy auditor shall be appointed, and that fees to the auditor shall be paid according to an approved bill in accordance with customary billing standards.
 
Election of the board and auditor
The meeting decided that Thomas Laurell, Stefan Scheding, Martin Olin and Katherine Flagg are re-elected as board members. Martin Olin was re-elected chairman of the board. Furthermore, the meeting decided that the company's auditor Öhrlings PricewaterhouseCoopers AB, with Mikael A Nilsson as chief auditor, be re-elected until the end of the annual general meeting held next financial year.
 
Decision on authorization for the board to issue shares, convertibles or warrants with preferential rights for the company's shareholders.
The annual general meeting approved the board's proposal for authorization for the board to, on one or more occasions before the next annual general meeting, within the limits of the articles of association, only with preferential rights for the company's shareholders, decide on new issue of shares or issue of convertibles or warrants. Issuance must be possible against cash payment or set-off.
 
Decision on authorization for the board to issue shares, convertibles or warrants without preferential rights for the company's shareholders.
The annual general meeting approved the board's proposal to authorize the board to decide on a new issue of shares or issue of convertibles or warrants on one or more occasions before the next annual general meeting, deviating from the shareholders' pre-emptive rights. The authorization is limited in such a way that the number of shares, after a fully subscribed new issue, full utilization of warrants or full conversion, does not increase by more than fifteen (15) percent of the number of shares outstanding at the time of this meeting.
 
Miscellaneous
The meeting decided to authorize the board, or whoever the board appoints, to carry out the minor adjustments that prove necessary when registering the decisions.
 
Lund in April 2024
AcouSort AB (publ)
THE BOARD OF DIRECTORS